KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) FCF Margin (2016 - 2026)

Emergent BioSolutions has reported FCF Margin over the past 16 years, most recently at 23.19% for Q1 2026.

  • For Q1 2026, FCF Margin fell 1747.0% year-over-year to 23.19%; the TTM value through Mar 2026 reached 21.5%, up 605.0%, while the annual FY2025 figure was 22.75%, 1731.0% up from the prior year.
  • FCF Margin for Q1 2026 was 23.19% at Emergent BioSolutions, down from 57.83% in the prior quarter.
  • Over five years, FCF Margin peaked at 85.8% in Q2 2024 and troughed at 116.74% in Q1 2023.
  • A 5-year average of 0.63% and a median of 5.72% in 2025 define the central range for FCF Margin.
  • Biggest five-year swings in FCF Margin: plummeted -10014bps in 2023 and later surged 11963bps in 2024.
  • Year by year, FCF Margin stood at 53.18% in 2022, then plummeted by -107bps to 3.72% in 2023, then crashed by -1006bps to 41.19% in 2024, then skyrocketed by 240bps to 57.83% in 2025, then crashed by -140bps to 23.19% in 2026.
  • Business Quant data shows FCF Margin for EBS at 23.19% in Q1 2026, 57.83% in Q4 2025, and 4.33% in Q3 2025.